medigraphic.com
ISSN 1405-8871 (Print)

2023, Number 2

<< Back Next >>

Aten Fam 2023; 30 (2)

Characterization of Patients with Type 2 Diabetes Mellitus and covid-19 in Primary Care

Morales-González E, Vázquez-Morales G, Sánchez-Escalante VC

Language: Spanish
References: 36
Page: 106-112
PDF size: 170.76 Kb.


ABSTRACT

Objectives: To describe the characteristics of the population diagnosed with type 2 Diabetes Mellitus (DM2) infected by SARS-COV-2, and to evaluate whether there is an association between DM2 history and COVID-19 severity. Methods: non-probabilistic by convenience sampling, information was obtained from the Online Notification System for Epidemiological Surveillance (SINOLAVE) of the Family Medicine Unit No. 28 of the Mexican Institute of Social Security. A total of 1688 confirmed cases of COVID- 19 were identified and grouped into patients with and without DM2. Bivariate statistical analysis was performed with Excel 2019 and Stata v. 15.1 programs; measures of association were used using Poisson logistic regression and χ2 test with statistical significance ‹0.05. Results: it was observed that, in patients with COVID-19 and DM2, the prevalence ratio of severe acute respiratory infection, diagnosis of pneumonia, hospitalization, and death were higher compared to the group without DM2. Conclusion: the frequency, of unfavorable characteristics, was higher in the group of patients with DM2. Health conditions caused by COVID-19 reinforce the relevance of an intentional search for undiagnosed diabetic patients, untreated or under treatment with poor glycemic control, in order to avoid major health complications.


REFERENCES

  1. Secretaria de Salud. Boletín Estadístico sobre el excesode mortalidad por todas las causas durante laemergencia COVID-19 [Internet]. [Citado 2022May 12]. Disponible en: https://coronavirus.gob.mx/wp-content/uploads/2020/10/BoletinIV_ExcesoMortalidad_SE39MX21102020.pdf

  2. Basto-Abreu A, Barrientos-Gutiérrez T, Rojas-Martínes R, et al. Prevalencia de diabetes y descontrolglucémico en México: resultados de laENSANUT 2016. Salud Publica de México.2020;62(1):50-9. DOI: 10.21149/10752

  3. Secretaría de Salud. Declaratoria de EmergenciaEpidemiologica [Internet]. [Citado 2022 May12]. Disponible en: http://www.cenaprece.salud.gob.mx/programas/interior/emergencias/descargas/pdf/DeclaratoriaEmergenciaEpidemiologicaEE-

  4. 4-16.pdf4. Dirección General de Epidemiología. PanoramaEpidemiológico de las Enfermedades no Trasmisiblesen México [Internet]. [Citado 2022 May 12].Disponible en: https://www.gob.mx/cms/uploads/attachment/file/745354/PanoEpi_ENT_Cierre2021.pdf

  5. Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiologyto clinical management. Nat Rev Endocrinol.2021;17(1):11-30. DOI: 10.1038/s41574-020-00435-4

  6. Hartmann-Boyce J, Morris E, Goyder C, KintonJ, Perring J, Nunan D, et al. Diabetes andCOVID-19: Risks, Management, and LearningsFrom Other National Disasters. Diabetes Care.2020;43(8):1695-1703. DOI: 10.2337/dc20-1192

  7. Ugwueze CV, Ezeaokpo BC, Nnolim BI, AgimEA, Anikpo NC, Onyekachi KE. COVID-19 andDiabetes Mellitus: The Link and Clinical Implications.Dubai Diabetes Endocrinol J. 2020;26:69-77. DOI: 10.1159/000511354

  8. Torres-Tamayo M, Caracas-Portillo NA, Peña-AparicioB, Juárez-Rojas JG, Medina-Urrutia AX, Martínez-Alvarado MDR. Coronavirus infection inpatients with diabetes. Cardiovasc and Metab Sci.2020;31(supl-3):s235-246. DOI: 10.35366/93954

  9. Parra-Bracamonte GM, Lopez-Villalobos N, Parra-Bracamonte FE. Clinical characteristics and riskfactors for mortality of patients with COVID-19in a large data set from Mexico. Ann Epidemiol.2020;52:93-98. DOI: 10.1016/j.annepidem.2020.08.005

  10. Pérez-Martínez P, Carrasco Sánchez FJ, CarreteroGómez J, Gómez-Huelgas R. Resolviendo una delas piezas del puzle: COVID-19 y diabetes tipo2. Rev Clin Esp. 2020;220(8):507-510. DOI:10.1016/j.rce.2020.05.003

  11. Seiglie J, Platt J, Cromer SJ, Bunda B, Foulkes AS,Bassett IV, Hsu J, et al. Diabetes as a risk factor forpoor early outcomes in patients hospitalized withCOVID-19. Diabetes Care. 2020;43:2938-2944.DOI: 10.2337/dc20-1506

  12. Guo W, Li M, Dong Y, Zhou H, Zhang Z, TianC, et al. Diabetes is a risk factor for the progressionand prognosis of COVID-19. Diabetes MetabSyndr Clin Res Rev. 2020;36:e3319.

  13. OECD, Health at Glance 2021: OECD indicators[Internet]. [Citado 2022 May 12]. Disponible en:https://doi.org/10.1787/ae3016b9-en

  14. Organización Panamericana de la Salud, ActualizaciónEpidemiológica Enfermedad por coronavirus[Internet]. [Citado 2022 May 12]. Disponible en:https://www.paho.org/es/documentos/actualizacion-epidemiologica-enfermedad-por-coronaviruscovid-19-26-agosto-2020

  15. Organización Panamericana de la Salud, OrganizaciónMundial de la Salud. Actualización Epidemiológica:Enfermedad por coronavirus (COVID-19)[Internet]. [Citado 2022 May 12]. Disponible en:https://www.paho.org/es/documentos/actualizacion-epidemiologica-enfermedad-por-coronaviruscovid-19-9-febrero-2021

  16. Ortiz-Brizuela E, Villanueva-Reza M, González-Lara MF, Tamez-Torres KM, Román-Montes CM,Díaz-Mejía BA, et al. Clinical and EpidemiologicalCharacteristics of Patients Diagnosed WithCOVID-19 in a Tertiary Care Center in MexicoCity: a Prospective Cohort Study. Rev InvestiClin. 2020;72(3):165-177. DOI: 10.24875/RIC.20000211

  17. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A, González-Díaz A,Márquez-Salinas A, et al. Predicting MortalityDue to SARS-CoV-2: A Mechanistic ScoreRelating Obesity and Diabetes to COVID-19Outcomes in Mexico. J Clin Endocrinol Metab.2020;105(8):2752-2761. DOI: 10.1210/clinem/dgaa346

  18. Fathi M, Vakili K, Sayehmiri F, MohamadkhaniA, Hajiesmaeili M, Rezaei-Tavirani M, et al. Theprognostic value of comorbidity for the severity ofCOVID-19: A systematic review and meta-analysisstudy. PLoS One. 2021;16(2):e0246190. DOI:10.1371/journal.pone.0246190

  19. Carrillo-Vega MF, Salinas-Escudero G, García-Peña C, Gutiérrez-Robledo LM, Parra-RodríguezL. Early estimation of the risk factors for hospitalizationand mortality by COVID-19 in Mexico.PLoS One. 2020;15(9):e0238905. DOI: 10.1371/journal.pone.0238905

  20. Chen Y, Yang D, Cheng B, Chen J, Peng A, YangC, et al. Clinical Characteristics and Outcomes ofPatients with Diabetes and COVID-19 in Associationwith Glucose-Lowering Medication. DiabetesCare. 2020;43(7):1399-1407. DOI: 10.2337/dc20-0660

  21. Corona G, Pizzocaro A, Vena W, Rastrelli G, SemeraroF, Isidori AM, et al. Diabetes is most importantcause for mortality in COVID‑19 hospitalizedpatients : Systematic review and meta‑analysis. RevEndocr Metab Disord. 2021;22:275-296. DOI:10.1007/s11154-021-09630-8

  22. Denova-Gutiérrez E, Lopez-Gatell H, Alomia-ZegarraJL, López-Ridaura R, Zaragoza-Jimenez CA,Dyer-Leal DD, et al. The Association of Obesity,Type 2 Diabetes, and Hypertension with SevereCoronavirus Disease 2019 on Admission AmongMexican Patients. Obesity. 2020;28(10):1826-1832. DOI: 10.1002/oby.22946

  23. Secretaría de Salud. Panorama epidemiológico delas enfermedades no trasmisibles en México [Internet].[Citado 2022 May 13]. Disponible en:https://www.gob.mx/cms/uploads/attachment/file/665694/PanoEpi_ENT_Junio_2021.pdf

  24. Instituto Nacional de Estadística y Geografía. [Internet].[Citado 2022 May 15]. Disponible en:https://www.inegi.org.mx/contenidos/saladeprensa/boletines/2021/EstSociodemo/DefuncionesRegistradas2020_Pre_07.pdf

  25. Secretaria de Salud. Lineamiento estandarizadopara la vigilancia epidemiologica y por laboratoriode la enfermedad respiratoria viral [Internet].[Citado 2022 May 15]. Disponible en: https://coronavirus.gob.mx/wpcontent/uploads/2021/02/Lineamiento_VE_y_Lab_Enf_Viral_Ene-2021_290121.pdf

  26. McGurnaghan SJ, Weir A, Bishop J, KennedyS, Blackbourn LAK, McAllister DA, et al. Risksof and risk factors for COVID-19 disease inpeople with diabetes: a cohort study of the totalpopulation of Scotland. Lancet Diabetes Endocrinol.2021;9:82-93. DOI: 10.1016/S2213-8587(20)30405-8

  27. Treviño JA. Demografía, comorbilidad y condicionesmédicas de los pacientes hospitalizados porCOVID-19 en México. MARLAS. 2020;4(1):49-70. DOI: 10.23870/marlas.317

  28. OPS. Guía operativa para la vigilancia centinela deETI e IRAG [Internet]. [Citado 2022 May 13].Disponible en: https://www.paho.org/hon/dmdocuments/Vigcentinela301108b.pdf

  29. Solís P, Carreño H. COVID-19 Fatality and ComorbidityRisk Factors among Diagnosed Patientsin Mexico. medRxiv 2020.04.21.20074591. DOI:https://doi.org/10.1101/2020.04.21.20074591

  30. Ciardullo S, Zerbini F, Perra S, Muraca E, CannistraciR, Lauriola M, et al. Impact of diabetes onCOVID‑19 related in hospital mortality : a retrospectivestudy from Northern Italy. J EndocrinolInvest. 2021;44:843-850. DOI: 10.1007/s40618-020-01382-7

  31. Al Argan R, Alkhafaji D, Al Elq A, Albaker W,Alqatari S, Alzaki A, et al. The Impact of DiabetesMellitus and Hyperglycemia on the Severityand Outcome of Patients with COVID-19Disease : A Single-Center Experience. Int J GenMed. 2021;14:9445-9457. DOI: 10.2147/IJGM.S338800

  32. Al-Ozairi E, Brown R, Hamdan Y, AlabdullahL, Voase N, Al Kandari J, et al. Risk of mortalityamong inpatients with COVID-19 and type2 diabetes: National data from Kuwait. EndocrinolDiab Metab. 2021;4:e00287. DOI: 10.1002/edm2.287

  33. Leon-Abarca JA, Portmann-Baracco A, Bryce-AlbertiM, Ruiz-Sánchez C, Accinelli RA, Soliz J, etal. Diabetes increases the risk of COVID-19 in analtitude dependent manner : An analysis of 1, 280,806 Mexican patients. PLoS One. 2021;16(8):e0255144. DOI:10.1371/journal.pone.0255144

  34. Rawshani A, Kjölhede EA, Rawshani A, SattarN, Eeg-Olofsson K, Adiels M, et al. Severe COVID-19 in people with type 1 and type 2 diabetesin Sweden : A nationwide retrospective cohortstudy. Lancet Regional Health. 2021;4:100105.DOI: 10.1016/j.lanepe.2021.100105

  35. Woolcott OO, Castilla-Bancayán JP. The effect ofage on the association between diabetes and mortalityin adult patients with COVID‑19 in Mexico.Sci Rep. 2021;11:8386. DOI: 10.1038/s41598-021-88014-z

  36. Secretaria de Salud. 36° informe epidemiológicode la situación de COVID-19 [Internet]. [Citado2022 May 13]. Disponible en: https://www.gob.mx/cms/uploads/attachment/file/637206/Informe_COVID-19_2020.12.28.pdf.




2020     |     www.medigraphic.com